KR20210058902A - sPD-1 변이체-FC 융합 단백질 - Google Patents

sPD-1 변이체-FC 융합 단백질 Download PDF

Info

Publication number
KR20210058902A
KR20210058902A KR1020217010801A KR20217010801A KR20210058902A KR 20210058902 A KR20210058902 A KR 20210058902A KR 1020217010801 A KR1020217010801 A KR 1020217010801A KR 20217010801 A KR20217010801 A KR 20217010801A KR 20210058902 A KR20210058902 A KR 20210058902A
Authority
KR
South Korea
Prior art keywords
spd
variant
domain
fusion protein
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217010801A
Other languages
English (en)
Korean (ko)
Inventor
아마토 제이. 지아키아
토드 에이. 아길레라
미할리스 에스. 카리올리스
유 미아오
카우식 탁카르
씬 에릭 장
Original Assignee
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티
악소 바이오파마슈티컬 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티, 악소 바이오파마슈티컬 인코포레이티드 filed Critical 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티
Publication of KR20210058902A publication Critical patent/KR20210058902A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020217010801A 2018-09-14 2019-09-12 sPD-1 변이체-FC 융합 단백질 Ceased KR20210058902A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862731488P 2018-09-14 2018-09-14
US62/731,488 2018-09-14
US201962888320P 2019-08-16 2019-08-16
US62/888,320 2019-08-16
PCT/US2019/050742 WO2020056085A1 (en) 2018-09-14 2019-09-12 Spd-1 variant - fc fusion proteins

Publications (1)

Publication Number Publication Date
KR20210058902A true KR20210058902A (ko) 2021-05-24

Family

ID=68211179

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217010801A Ceased KR20210058902A (ko) 2018-09-14 2019-09-12 sPD-1 변이체-FC 융합 단백질

Country Status (11)

Country Link
US (2) US11498955B2 (cg-RX-API-DMAC7.html)
EP (1) EP3850003A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021535761A (cg-RX-API-DMAC7.html)
KR (1) KR20210058902A (cg-RX-API-DMAC7.html)
CN (1) CN112969710A (cg-RX-API-DMAC7.html)
AU (1) AU2019338416A1 (cg-RX-API-DMAC7.html)
CA (1) CA3109983A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ774126A (cg-RX-API-DMAC7.html)
SG (1) SG11202101904UA (cg-RX-API-DMAC7.html)
TW (2) TW202348622A (cg-RX-API-DMAC7.html)
WO (1) WO2020056085A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023048518A1 (ko) * 2021-09-24 2023-03-30 바이오엔시스템스 주식회사 Pd-1 및 il-15를 포함하는 융합단백질 이량체 및 이의 용도

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164428A1 (en) * 2015-04-06 2016-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
EP3991741A1 (en) * 2020-11-02 2022-05-04 Klinikum rechts der Isar der Technischen Universität München An immune checkpoint-modulating vsv-ndv hybrid virus for oncolytic virus immonotherapy of cancer
US20230414660A1 (en) * 2020-11-13 2023-12-28 Ludwig Institute For Cancer Research Ltd Pd-1 decoy variants for immunotherapy
WO2022137186A1 (en) 2020-12-23 2022-06-30 Crispr Therapeutics Ag Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor
CN117321079A (zh) * 2021-01-11 2023-12-29 优特力克斯有限公司 包含抗4-1bb抗体及pd-1蛋白或其片段的双特异性表位结合蛋白及其用途
EP4288080A1 (en) * 2021-02-04 2023-12-13 Helsingin Yliopisto A cross-hybrid fc-fusion polypeptide targeting pd-l1 and methods and uses related thereto
WO2022187488A2 (en) * 2021-03-03 2022-09-09 Shattuck Labs, Inc. Mutant pd-1 extracellular domains
US20220387488A1 (en) 2021-05-12 2022-12-08 Crispr Therapeutics Ag Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies
EP4346875A4 (en) * 2021-05-28 2025-04-16 Akso Biopharmaceutical, Inc. BISPECIFIC FC FUSION PROTEINS WITH SPD-1 AND IL-15

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110034373A1 (en) * 2007-08-03 2011-02-10 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
CN103261217B (zh) * 2010-11-11 2017-04-26 港大科桥有限公司 可溶性 pd‑1变体、融合构建体及其用途
US20150368316A1 (en) * 2013-02-07 2015-12-24 Albert Einstein College Of Medicine Of Yeshiva University A selective high-affinity immune stimulatory reagent and uses thereof
WO2016023001A1 (en) 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Multispecific high affinity pd-1 agents and methods of use
EP3177640B1 (en) * 2014-08-08 2020-05-06 The Board of Trustees of the Leland Stanford Junior University High affinity pd-1 agents and methods of use
WO2016164428A1 (en) * 2015-04-06 2016-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
US10844392B2 (en) * 2015-06-05 2020-11-24 Ibio, Inc. Materials and methods for producing endostatin fusion polypeptides in plant cells
PL3368572T5 (pl) * 2015-10-02 2026-07-20 Les Laboratoires Servier Przeciwciała anty-PD-1 oraz kompozycje
WO2017123548A1 (en) 2016-01-14 2017-07-20 Seattle Children's Hospital (dba Seattle Children's Research Institute) Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment
WO2018104473A1 (en) * 2016-12-07 2018-06-14 Oslo Universitetssykehus Hf Compositions and methods for cell therapy
WO2019241758A1 (en) * 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023048518A1 (ko) * 2021-09-24 2023-03-30 바이오엔시스템스 주식회사 Pd-1 및 il-15를 포함하는 융합단백질 이량체 및 이의 용도

Also Published As

Publication number Publication date
WO2020056085A1 (en) 2020-03-19
EP3850003A1 (en) 2021-07-21
US20230131056A1 (en) 2023-04-27
CA3109983A1 (en) 2020-03-19
TW202348622A (zh) 2023-12-16
NZ774126A (en) 2023-05-26
AU2019338416A1 (en) 2021-04-29
US11498955B2 (en) 2022-11-15
US20200181231A1 (en) 2020-06-11
CN112969710A (zh) 2021-06-15
JP2021535761A (ja) 2021-12-23
SG11202101904UA (en) 2021-04-29
TWI815964B (zh) 2023-09-21
TW202023604A (zh) 2020-07-01

Similar Documents

Publication Publication Date Title
US20230131056A1 (en) sPD-1 VARIANT – FC FUSION PROTEINS
US20230055445A1 (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
TWI853809B (zh) 包含4-1bbl之靶向her2的抗原結合分子
JP7675739B2 (ja) Ox40およびfapを標的化する二重特異性抗原結合分子
JP2023106405A (ja) IL-15/IL-15RアルファFc融合タンパク質およびPD-1抗体の断片を含む二重特異性ヘテロ二量体融合タンパク質
CN107614013B (zh) 结合lag-3的分子和其使用方法
KR20210010862A (ko) IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도
US20250215081A1 (en) Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
KR20180028560A (ko) Csf1r에 결합하는 항체들
RU2785993C2 (ru) ГИБРИДНЫЕ БЕЛКИ ВАРИАНТА sPD-1—FC
HK40053326A (en) Spd-1 variant - fc fusion proteins
RU2854454C1 (ru) Биспецифические антигенсвязывающие молекулы, нацеливающиеся на ox40 и fap
NZ796397A (en) sPD-1 variant - Fc fusion proteins
WO2025149633A1 (en) Bispecific antigen binding proteins
CN119451985A (zh) 在组合疗法中能够结合cd27的结合剂
HK40106274A (en) Agonistic cd28 antigen binding molecules targeting epcam
HK40054597B (en) Bispecific antigen binding molecules comprising lipocalin muteins

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210412

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220913

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20250328

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250610

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D